Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study

Our study suggests that while antithrombotic therapy reduces 28-day mortality, it significantly increases rebleeding risk. Notably, the use of anticoagulants or combination therapy is linked to the highest rebleeding risk, compared to antiplatelets. Additionally, resuming antithrombotic therapy too early (i.e., within 3 days) may further elevate the risk of mortality.